Table 3.

Prediction of Neurogenic Bowel Dysfunction Score and Actionable Bladder Symptom Screening Tool score

Score		Nagelkerke R2	R2 change	P-value for change	Coefficient	95% CI	Beta coefficient	P-value
Neurogenic Bowel Dysfunction Score
	First step	0.11	-	-
	Second step	0.17	0.06	0.09
	Third step	0.21	0.04	0.01*
Variables (third step)
	Female vs. male				0.47	-1.55 to 2.50	0.04	0.65
	Age				-0.03	-0.14 to 0.08	-0.06	0.58
	Education (yr)				-0.16	-0.45 to 0.14	-0.10	0.29
	Patients with ambulatory restriction vs. fully ambulatory				0.21	-2.66 to 3.08	0.02	0.88
	Secondary progressive vs. relapsing-remitting				1.99	-1.12 to 5.09	0.13	0.21
	Primary-progressive vs. relapsing-remitting				1.40	-4.16 to 6.96	0.04	0.62
	Disease duration				0.07	-0.08 to 0.22	0.08	0.36
	Annualized relapse rate				0.07	-2.51 to 2.65	0.00	0.96
	SDMT score				-0.10	-0.18 to -0.02	-0.30	0.01*
Actionable Bladder Symptom Screening Tool score
	First step	0.09	-	-
	Second step	0.16	0.06	0.06
	Third step	0.18	0.03	0.03*
Variables (third step)
	Female vs. male				0.03	-0.89 to 0.94	0.00	0.96
	Age				0.02	-0.03 to 0.07	0.10	0.35
	Education (yr)				-0.18	-0.32 to 0.08	-0.12	0.24
	Patients with ambulatory restriction vs. fully ambulatory				1.23	-0.14 to 2.60	0.20	0.08
	Secondary progressive vs. relapsing remitting				-0.07	-1.53 to 1.39	-0.01	0.92
	Primary-progressive vs. relapsing remitting				0.73	-1.80 to 3.26	0.05	0.57
	Disease duration				-0.01	-0.08 to 0.06	-0.03	0.76
	Annualized relapse rate				-0.49	-1.66 to 0.68	-0.07	0.41
	SDMT score				-0.03	-0.06 to 0.01	-0.21	0.04*

CI, confidence interval; SDMT, Symbol Digit Modality Test.

^*P<0.05, statistically significant difference.